Reviewing What Is Known of Sex Differences in Response to Established Longevity Interventions

Key Takeaways

• Female mice often outlive males but show higher disease burden
• Dietary restriction extends lifespan more in male rodents than females
• Genetic knockouts of growth pathways benefit one sex disproportionately
• Hormonal status modulates drug efficacy in aging studies
• Ignoring sex differences risks ineffective human therapies

Pulse Analysis

The disparity between lifespan and healthspan across sexes is a well‑documented phenomenon. Women generally live longer than men, yet they experience a higher burden of chronic conditions, a trend mirrored in mouse models where females often survive longer but accumulate more pathology. This paradox underscores the importance of dissecting sex‑specific biology—from chromosome composition to hormonal milieu—to explain why interventions that extend life in one sex may fall short or even harm the other.

A growing body of evidence shows that classic longevity interventions, such as caloric restriction, rapamycin treatment, and modulation of the growth hormone/IGF‑1 axis, produce markedly different outcomes in male versus female rodents. For instance, caloric restriction tends to boost median lifespan more robustly in males, while certain genetic knockouts of growth pathways confer greater benefits to females. Hormonal differences, including estrogen‑mediated signaling and X‑chromosome dosage compensation, appear to influence drug metabolism and tissue response, suggesting that the efficacy of pharmacological agents is tightly linked to sex‑specific physiology.

These findings have direct implications for translational research and drug development. Regulatory agencies now require sex as a biological variable in preclinical studies, but many labs still overlook this nuance, risking costly failures in human trials. Incorporating sex‑balanced designs, stratified data analysis, and mechanistic studies on hormonal and chromosomal influences will accelerate the discovery of truly universal—or deliberately tailored—anti‑aging therapies. As the biotech industry invests heavily in longevity solutions, a rigorous, sex‑aware approach will be essential to deliver safe, effective treatments to the broader population.